Cargando…

Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials

BACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Luyao, Li, Libing, Ma, Fujin, Ma, Fuyun, Ma, Shujia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553141/
https://www.ncbi.nlm.nih.gov/pubmed/37811103
http://dx.doi.org/10.1097/MS9.0000000000001244
_version_ 1785116101730893824
author Ma, Luyao
Li, Libing
Ma, Fujin
Ma, Fuyun
Ma, Shujia
author_facet Ma, Luyao
Li, Libing
Ma, Fujin
Ma, Fuyun
Ma, Shujia
author_sort Ma, Luyao
collection PubMed
description BACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have not been systematically evaluated by economics. The purpose of this study was to assess the efficacy, safety, and economy of the SSYX in the treatment of arrhythmia in patients with coronary heart disease. METHODS: With “Shensong Yangxin Capsules” “Coronary Heart Disease” “Coronary Atherosclerotic Heart Disease”and “Arrhythmia” as the subject words, the relevant journals and conference papers were searched manually in China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP, PubMed, Web Of Science, CBM, Embase and The Cochrane Library. The literature of randomized controlled trials of SSYX in the treatment of coronary heart disease arrhythmia was searched until November 2022. All data were analyzed using RevMan 5.3 Sotware and combined with cost-effectiveness for economic evaluation. RESULTS: Twenty randomized controlled trials were included in this study, with a total of 2011 cases. The meta-analysis showed that the therapeutic effect of SSYX-metoprolol is superior to that of metoprolol alone. SSYX is superior to amiodarone in improving the total clinical effective rate, reducing the incidence of adverse reactions, and reducing the junction premature beats. There was no significant difference between the SSYX and amiodarone in the curative effect of ECG, ventricular premature complexes, and atrial premature beats. The results of pharmacoeconomics show that SSYX has a cost-effectiveness advantage in treating coronary heart disease arrhythmia. Single-factor sensitivity analysis also confirmed the stability of the results. In summary, SSYX has a curative effect, safety, and economy in treating coronary heart disease arrhythmia.
format Online
Article
Text
id pubmed-10553141
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105531412023-10-06 Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials Ma, Luyao Li, Libing Ma, Fujin Ma, Fuyun Ma, Shujia Ann Med Surg (Lond) Reviews BACKGROUND: Shensong Yangxin Capsules (SSYX) is a proprietary Chinese medicine commonly, used in the treatment of arrhythmia. In recent years, a flurry of randomized controlled trials of SSYX was reported in the treatment of Coronary heart disease arrhythmia in China. However, these experiments have not been systematically evaluated by economics. The purpose of this study was to assess the efficacy, safety, and economy of the SSYX in the treatment of arrhythmia in patients with coronary heart disease. METHODS: With “Shensong Yangxin Capsules” “Coronary Heart Disease” “Coronary Atherosclerotic Heart Disease”and “Arrhythmia” as the subject words, the relevant journals and conference papers were searched manually in China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP, PubMed, Web Of Science, CBM, Embase and The Cochrane Library. The literature of randomized controlled trials of SSYX in the treatment of coronary heart disease arrhythmia was searched until November 2022. All data were analyzed using RevMan 5.3 Sotware and combined with cost-effectiveness for economic evaluation. RESULTS: Twenty randomized controlled trials were included in this study, with a total of 2011 cases. The meta-analysis showed that the therapeutic effect of SSYX-metoprolol is superior to that of metoprolol alone. SSYX is superior to amiodarone in improving the total clinical effective rate, reducing the incidence of adverse reactions, and reducing the junction premature beats. There was no significant difference between the SSYX and amiodarone in the curative effect of ECG, ventricular premature complexes, and atrial premature beats. The results of pharmacoeconomics show that SSYX has a cost-effectiveness advantage in treating coronary heart disease arrhythmia. Single-factor sensitivity analysis also confirmed the stability of the results. In summary, SSYX has a curative effect, safety, and economy in treating coronary heart disease arrhythmia. Lippincott Williams & Wilkins 2023-09-01 /pmc/articles/PMC10553141/ /pubmed/37811103 http://dx.doi.org/10.1097/MS9.0000000000001244 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Reviews
Ma, Luyao
Li, Libing
Ma, Fujin
Ma, Fuyun
Ma, Shujia
Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
title Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
title_full Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
title_fullStr Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
title_full_unstemmed Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
title_short Efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
title_sort efficacy, safety, and economy of shensongyangxin capsules for the treatment of coronary heart disease arrhythmia: a meta-analysis of randomized controlled trials
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553141/
https://www.ncbi.nlm.nih.gov/pubmed/37811103
http://dx.doi.org/10.1097/MS9.0000000000001244
work_keys_str_mv AT maluyao efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials
AT lilibing efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials
AT mafujin efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials
AT mafuyun efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials
AT mashujia efficacysafetyandeconomyofshensongyangxincapsulesforthetreatmentofcoronaryheartdiseasearrhythmiaametaanalysisofrandomizedcontrolledtrials